Bioventus Inc. (BVS)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 6.78 |
| Open | 6.79 |
| Bid | 6.65 x 200 |
| Ask | 6.70 x 400 |
| Day's range | 6.43 - 6.83 |
| 52-week range | 2.59 - 7.01 |
| Volume | |
| Avg. volume | 268,725 |
| Market cap | 427.007M |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe
- Zacks
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases.
- Zacks
J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate
J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.
© 2024 Yahoo. All rights reserved.